Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorNewman, Craig G. J.
dc.contributor.authorBevins, Adam D.
dc.contributor.authorZajicek, John P.
dc.contributor.authorHodges, John R.
dc.contributor.authorVuillermoz, Emil
dc.contributor.authorDickenson, Jennifer M.
dc.contributor.authorKelly, Denise S.
dc.contributor.authorBrown, Simona
dc.contributor.authorNoad, Rupert F.
dc.date.accessioned2018-02-20T12:30:05Z
dc.date.available2018-02-20T12:30:05Z
dc.date.issued2018
dc.identifier251876410
dc.identifier7f14ad3b-4967-4a9d-8895-0f736ce49c97
dc.identifier85042103770
dc.identifier.citationNewman , C G J , Bevins , A D , Zajicek , J P , Hodges , J R , Vuillermoz , E , Dickenson , J M , Kelly , D S , Brown , S & Noad , R F 2018 , ' Improving the quality of cognitive screening assessments : ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-III ' , Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring , vol. 10 , pp. 182-187 . https://doi.org/10.1016/j.dadm.2017.12.003en
dc.identifier.issn2352-8729
dc.identifier.otherRIS: urn:AADD78DAEE17D25FFEC5C37917B25CF6
dc.identifier.otherORCID: /0000-0003-3481-825X/work/64034674
dc.identifier.urihttps://hdl.handle.net/10023/12759
dc.descriptionThe authors would like to acknowledge the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care in the South West Peninsula (PenCLAHRC) and Clinical Trials Methods in Neurodegenerative Diseases (Programme Grant RP-PG-0707-10124).en
dc.description.abstractIntroduction:  Ensuring reliable administration and reporting of cognitive screening tests are fundamental in establishing good clinical practice and research. This study captured the rate and type of errors in clinical practice, using the Addenbrooke's Cognitive Examination-III (ACE-III), and then the reduction in error rate using a computerized alternative, the ACEmobile app. Methods:  In study 1, we evaluated ACE-III assessments completed in National Health Service (NHS) clinics (n = 87) for administrator error. In study 2, ACEmobile and ACE-III were then evaluated for their ability to capture accurate measurement. Results:  In study 1, 78% of clinically administered ACE-IIIs were either scored incorrectly or had arithmetical errors. In study 2, error rates seen in the ACE-III were reduced by 85%–93% using ACEmobile. Discussion:  Error rates are ubiquitous in routine clinical use of cognitive screening tests and the ACE-III. ACEmobile provides a framework for supporting reduced administration, scoring, and arithmetical error during cognitive screening.
dc.format.extent6
dc.format.extent288115
dc.language.isoeng
dc.relation.ispartofAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoringen
dc.subjectScreening assessmenten
dc.subjectCognitive assessmenten
dc.subjectAlzheimer'sen
dc.subjectDementiaen
dc.subjectComputerizeden
dc.subjectAppen
dc.subjectUsabilityen
dc.subjectValidityen
dc.subjectAdministrator erroren
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectQA76 Computer softwareen
dc.subjectNDASen
dc.subject.lccRC0321en
dc.subject.lccQA76en
dc.titleImproving the quality of cognitive screening assessments : ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-IIIen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Cellular Medicine Divisionen
dc.identifier.doi10.1016/j.dadm.2017.12.003
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record